Skip to main content
. 2011 Aug 1;85(2):295–302. doi: 10.4269/ajtmh.2011.11-0076

Table 1.

Demographic and clinical characteristics of 2,058 patients and the percentage with antibiotic activity detected in their urine in the retrospective examination of inpatients in Vientiane and those with unexplained fever at Phalanxay

Study % Male Age/years* % < 15 years old No. of urine specimens No. (%) (95% confidence interval [CI]) with any antimicrobial activity in urine No. (%) (95%CI) urine samples containing antimicrobial activity according to species of target organism
E. coli B. stearothermophilus S. pyogenes
All in Vientiane 59.1 26 (0.005–93)1842 23.81842 1,844 916 (49.7) (47.4–52.0) 443/1840 (24.1) (22.1–26.0) 805/1839 (43.8) (41.5–46.0) 613/1840 (33.3) (31.2–35.5)
Central nervous system (CNS) infections 64.5 27 (0.01–84) 23.4 414 235 (56.8) (52.0–61.5) 154/410 (37.6) (32.9–42.3) 212/409 (51.8) (47.0–56.7) 189/410 (46.1) (41.3–50.9)
Typhus suspected without suspected CNS infection 60.8 29 (0.33–85) 6.0 663 246 (37.1) (33.4–40.8) 106 (16.0) (13.2–18.8) 202 (30.5) (27.0–34.0) 145 (21.9) (18.7–25.0)
Community-acquired septicemia alone suspected§ 54.9 22 (0.005–93)761 39.3761 763 433 (56.8) (53.3–60.3) 181 (23.7) (20.7–26.7) 389 (51.0) (47.4–54.5) 277 (36.3) (32.9–39.7)
All who had blood cultures taken 58.7 26 (0.005–93)1812 24.11812 1814 905 (49.9) (47.6–52.2) 433/1810 (23.9) (22.0–25.9) 796/1809 (44.0) (41.7–46.3) 605/1810 (33.4) (31.3–35.6)
All adults 59.1 1,404 653 (46.5) (43.9–49.1) 317/1401 (22.6) (20.4–24.8) 562/1399 (40.2) (37.6–42.7) 419/1400 (29.9) (27.5–32.3)
All children 58.9 438 263 (60.0) (55.5–64.6) 126/437 (28.8) (24.6–33.1) 243/438 (55.5) (50.8–60.1) 194 (44.3) (39.6–48.9)
Phalanxay 57.5 15 (3–80) 50 214 81 (37.9) (31.4–44.4) 29 (13.6) (9.0–18.1) 67 (31.3) (25.1–37.5) 44 (20.7) (15.2–26.1)213
All adults 57.0 107 43 (40.2) (30.9–49.5) 16 (15.0) (8.2–27.7) 36 (33.6) (24.7–42.6) 22 (20.8) (13.0–28.5)106
All children 57.9 107 38 (35.5) (26.4–44.6) 13 (12.2) (6.0–18.3) 31 (29.0) (20.4–37.6) 22 (20.6) (12.9–28.2)

Denominators are only shown if there are missing values. Number (%) or * Median (range).

Any patient with clinically suspected community-acquired infection of the CNS without contraindications to lumbar puncture in Vientiane. Clinically significant organisms were cultured from 33 of 414 (8.0%) patients who had cerebrospinal fluid (CSF) culture (S. pneumoniae [N = 8], S. suis [N = 1], K. pneumoniae [N = 1], C. neoformans [N = 20], and Mycobacterium tuberculosis [N = 3]). Polymerase chain reaction (20 and Mayxay M, unpublished) assays for S. pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type b in CSF were positive in an additional six patients with S. pneumoniae and two each with N. meningitidis and H. influenzae, giving a total of 43 of 414 (10.4%) of patients having proven bacterial/fungal meningitis.

Any patient with clinically suspected typhus, but without suspected CNS infection, in Vientiane. Thirty-eight (5.7%) had positive blood cultures (growing S. typhi [N = 19], E. coli [N = 9], B. pseudomallei [N = 4], K. pneumoniae [N = 2], Salmonella spp. [N = 1], S. pyogenes [N = 1], S. aureus [N = 1], and Aeromonas hydrophilia [N = 1]).

§

Any patient with clinically suspected community-acquired septicemia in Vientiane.

Clinically significant organisms were cultured from 109 of 1,844 (5.9%) patients who had blood cultures taken—Salmonella enterica serovar typhi (N = 34), E. coli (N = 23), Burkholderia pseudomallei (N = 9), S. aureus (N = 8), Klebsiella pneumoniae (N = 6), Salmonella spp. (N = 6), S. pyogenes (N = 3), S. pneumoniae (N = 9), A. hydrophila (N = 1), Edwardsiella tarda (N = 1), Group B Streptococcus (N = 1), S. suis (N = 1), Neisseria meningitidis (N = 1), Cryptococcus neoformans (N = 4), and Penicillium marneffei (N = 2).

Any patient, presenting at Phalanxay District Hospital, who the admitting physician thought may have malaria and performed slide microscopy and/or malaria rapid diagnostic test for P. falciparum (Paracheck, Orchid Industries, Goa, India) that were negative.